Stem Cell Clinic

Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in…

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (Celularity ), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, today announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM) in a poster presentation at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix, A.Z.

Results from pre-clinical studies demonstrated in vivo anti-GBM activity of CYNK-001. The positive results from these pre-clinical studies highlight the versatility and activity of our investigational, off-the-shelf, placental-derived NK cell therapy program, said Robert Hariri, M.D., Ph.D., Founder, Chairman and CEO at Celularity. There is a clear need for novel therapeutic approaches to the treatment of glioblastoma multiforme. We look forward to advancing our investigational programs and are optimistic about the possibility of bringing another therapeutic option to patients in need.

About CYNK-001CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. When derived from the placenta, these cells offer intrinsic safety and versatility, allowing potential use across a range of organs and tissues. CYNK-001 is currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and as a potential treatment option for various solid tumors.

About CelularityCelularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases. To learn more, please visit http://www.celularity.com.

Forward-Looking StatementsThis press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

See the rest here:
Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in...

Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean – PRNewswire

BEVERLY HILLS, California, Nov. 21, 2019 /PRNewswire/ -- Full Alliance Group, Inc. (OTCPK: FAGI) is pleased to announce the opening of two new EBO2 treatment offices.

Dr. Yu and his staff arrived in Boca Raton, Florida, and then the Cayman Islands earlier this week with two brand-new portable EBO2 units and are currently training Dr. Joseph Purita and his staff. Dr. Purita is well-known in the stem cell and regenerative medicine sector and is eager to implement our ozone technology within his thriving practice.He has offices in Boca Raton as well as in the Cayman Islands.

Dr. Purita's Pensum Regenerative Clinic in Grand Cayman already specializes in stem cell treatment and anti-aging.The addition of EBO2 technology is expected to work synergistically with the well-established stem cell protocols already in place at the clinic.

"Expanding our footprint to the East and South, as well as the Caribbean, has been a critical part of our strategic plan," said Dr. Brian Volpp, MD, CEO and President of Full Alliance Group, Inc. "We are grateful that Dr. Purita has committed to the Yu Method and that he has made the financial commitment for two of our new units.His reputation within the stem cell community should allow ozone therapy to become more mainstream as he gains more experience with integrating EBO2 into his existing protocols."

Also, we have been advised by our legal team that the third quarter financial filing must be made publicly available to all shareholders. Consequently, the filing has been posted on our website:https://FullAlliance.com

About Full Alliance Group Inc.

Full Alliance Group Inc. (OTCPK: FAGI) is a multi-faceted holding company with various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a wholly owned subsidiary of Full Alliance Group, develops, markets, and distributes a proprietary line of nutraceutical products. EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation, ozone exposure and blood filtration.The process filters blood in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply. The EBO2 unit is considered the world's most advanced medical ozone therapy.

For additional information regarding Full Alliance Group, visit, http://www.fullalliance.com.

Paul Brian Volpp, MD, MPH, President / CEO The Full Alliance Group

Forward-Looking StatementsThis shareholder update may contain a number of forward-looking statements. Words and variations of words such as: "expect", "goals", "could", "plans", "believe", "continue", "may", "will", and similar expressions are intended to identify our forward-looking statements, including but not limited to: our expectation for growth, benefits from brand-building, cost savings and margins. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Such factors include, but are not limited to: continued volatility of, and sharp increase in: costs/pricing actions, increased competition, ability to raise sufficient operating capital, risks from operating internationally, consumer weakness, weakness in economic conditions and tax law changes.

Full Alliance Group Inc. Investor RelationsDave DonlinEmail: Info@TheCervelleGroup.comPhone: (407) 490-6635Web: http://www.StockInvestorDaily.comVisit: http://www.fullalliance.comContact: ir@fullalliance.com

SOURCE Full Alliance Group, Inc.

Home

Continue reading here:
Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean - PRNewswire

Allogene and the need for a reliable cell source – Vantage

David Chang saw the end goal early. As chief medical officer of Kite Pharma, before that company was ever in allogeneic cell therapy, he did a deal with UCLA to secure a supply of pluripotent stem cells. Now, as chief executive of Allogene, he has repeated the trick, licensing in Notch Therapeutics stem cell technology this month.

Speaking to Vantage at this weeks Jefferies conference in London Mr Chang said that within a month of Allogenes creation he recognised the need to secure cell supply and of course he had done it before, at Kite. Any allogeneic cell therapy company at some point has to start thinking about renewable cell source, he states.

Since the 2017 approvals of Kymriah and Yescarta the development of autologous cell therapy products has stalled, and many investors see allogeneic, or off-the-shelf, therapy as the breakthrough that will move the needle.

However, the first generation of allogeneic players have hit production bottlenecks, and have struggled with cells derived from healthy donors; these tend to be heterogeneous and of variable quality not what is needed when the goal is to produce a reliable, universal product.

Single cell

Using induced pluripotent stem cells (iPSCs) as the source, however, is likened by another player in this field, Fate Therapeutics, to going by monoclonal antibody principles: starting from a single cell line.

The idea is that virtually any adult cell can, in a petri dish, be regressed to an iPSC phenotype, and this, using clever science, can then be reprogrammed into a defined mature cell that can be infinitely expanded.

What the iPSC is differentiated into depends on each developers focus: Allogene is clearly working on T cells, whereas Fate is initially targeting NK cell therapeutics. Each comes with its own degree of difficulty, and Mr Chang argues that differentiating iPSCs into NK cells is possibly easy.

He says Allogene actively went out to source such a technology, and there were several potential partners, though of course the UCLA work was no longer available. Without going into scientific minutiae, the Notch teams underlying concept is the same as that of UCLA, says Mr Chang.

However, the Notch approach is a serum-free, cell-free system to differentiate iPSCs. The UCLA technology, pioneered by Dr Gay Crooks andalso known as an artificial thymic organoid, uses so-called feeder cells on top of which the desired iPSC-derived cells are differentiated.

All that said, the Notch deal caused a degree of consternation, with some Allogene investors seeing it as demonstrating a lack of confidencein Cellectiss donor-derived approach.

Mr Chang says he was taken aback by such pushback, and stresses that the transition from autologous to allogeneic is not a bet on a single technology but a stepwise process. Nevertheless, the clear implication is that, in time, Cellectis's current healthy donor cell source approach will become obsolete.

Though Mr Chang accepts that the science is not quite there to implement the Notch technology into clinical programmes, he says: The way we see the future, whether its five or 10 years down the line, is in the renewable cell source.

Go here to see the original:
Allogene and the need for a reliable cell source - Vantage

Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis – Downey Magazine

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Request a PDF Brochure of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

The rest is here:
Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis - Downey Magazine